NO20015288L - Anvendelse av makrolide forbindelser for behandling av tört vye - Google Patents

Anvendelse av makrolide forbindelser for behandling av tört vye

Info

Publication number
NO20015288L
NO20015288L NO20015288A NO20015288A NO20015288L NO 20015288 L NO20015288 L NO 20015288L NO 20015288 A NO20015288 A NO 20015288A NO 20015288 A NO20015288 A NO 20015288A NO 20015288 L NO20015288 L NO 20015288L
Authority
NO
Norway
Prior art keywords
treatment
dry eye
macrolide compounds
macrolide
compounds
Prior art date
Application number
NO20015288A
Other languages
English (en)
Other versions
NO20015288D0 (no
Inventor
Ryuji Ueno
Original Assignee
Sucampo Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22452015&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20015288(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sucampo Ag filed Critical Sucampo Ag
Publication of NO20015288L publication Critical patent/NO20015288L/no
Publication of NO20015288D0 publication Critical patent/NO20015288D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
NO20015288A 1999-04-30 2001-10-29 Anvendelse av makrolide forbindelser for behandling av tört öye NO20015288D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13200999P 1999-04-30 1999-04-30
PCT/JP2000/002756 WO2000066122A1 (en) 1999-04-30 2000-04-26 Use of macrolide compounds for the treatment of dry eye

Publications (2)

Publication Number Publication Date
NO20015288L true NO20015288L (no) 2001-10-29
NO20015288D0 NO20015288D0 (no) 2001-10-29

Family

ID=22452015

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20015288A NO20015288D0 (no) 1999-04-30 2001-10-29 Anvendelse av makrolide forbindelser for behandling av tört öye

Country Status (23)

Country Link
EP (1) EP1173177B2 (no)
JP (2) JP5036934B2 (no)
KR (1) KR20020015316A (no)
CN (1) CN1190194C (no)
AR (1) AR023807A1 (no)
AT (1) ATE281167T1 (no)
AU (1) AU777915B2 (no)
BR (1) BR0011225A (no)
CA (1) CA2372448A1 (no)
CZ (1) CZ20013769A3 (no)
DE (1) DE60015516T2 (no)
ES (1) ES2232439T3 (no)
HK (2) HK1043321B (no)
HU (1) HUP0200864A3 (no)
IL (1) IL146162A0 (no)
MX (1) MXPA01010988A (no)
NO (1) NO20015288D0 (no)
NZ (1) NZ515339A (no)
PT (1) PT1173177E (no)
TR (1) TR200103119T2 (no)
TW (1) TWI230066B (no)
WO (1) WO2000066122A1 (no)
ZA (1) ZA200108905B (no)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000066122A1 (en) * 1999-04-30 2000-11-09 Sucampo Ag Use of macrolide compounds for the treatment of dry eye
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
KR20040019034A (ko) 2001-07-06 2004-03-04 수캄포 아게 인터루킨 2 억제제 및 항미생물제를 포함하는 국소 투여용조성물
PE20030828A1 (es) * 2002-03-04 2003-11-04 Novartis Ag Composicion oftalmica que comprende ascomicina
MXPA05001575A (es) * 2002-08-09 2005-08-19 Sucampo Pharmaceuticals Inc Composiciones farmaceuticas que comprenden derivados de fk506 y su uso para el tratamiento de enfermedades alergicas.
US7354574B2 (en) 2002-11-07 2008-04-08 Advanced Ocular Systems Limited Treatment of ocular disease
US20040198763A1 (en) * 2003-01-16 2004-10-07 Sucampo Ag Method of treating dry eye with a macrolide compound
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
US7083802B2 (en) * 2003-07-31 2006-08-01 Advanced Ocular Systems Limited Treatment of ocular disease
US7087237B2 (en) 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
US7083803B2 (en) 2003-09-19 2006-08-01 Advanced Ocular Systems Limited Ocular solutions
JP4249185B2 (ja) 2003-10-06 2009-04-02 株式会社オフテクス 涙液異常の治療のための眼科用組成物
DK1848431T3 (en) 2005-02-09 2016-04-18 Santen Pharmaceutical Co Ltd LIQUID FORMULATIONS FOR TREATMENT OF DISEASES OR CONDITIONS
AU2006270041B2 (en) 2005-07-18 2011-08-18 Minu, Llc Enhanced ocular neuroprotection/neurostimulation
AU2007212271B2 (en) 2006-02-09 2012-11-01 Santen Pharmaceutical Co., Ltd. Stable formulations, and methods of their preparation and use
BRPI0709016A2 (pt) 2006-03-23 2011-06-21 Macusight Inc formulações e métodos para doenças ou condições relacionadas com a permeabilidade vascular
EP2335735A1 (en) * 2009-12-14 2011-06-22 Novaliq GmbH Pharmaceutical composition for treatment of dry eye syndrome
WO2018220444A2 (en) * 2017-05-30 2018-12-06 Eximore Ltd. Compositions and methods for treating dry eye syndrome delivering antibiotic macrolide
US11766421B2 (en) 2017-09-25 2023-09-26 Surface Ophthalmics, Inc. Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease
AU2019417161B2 (en) 2018-12-27 2023-06-15 Surface Ophthalmics, Inc. Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69016515T2 (de) * 1989-07-05 1995-06-08 Fujisawa Pharmaceutical Co Wässriges flüssiges Mittel zur äusserlichen Anwendung.
ATE198708T1 (de) * 1991-04-26 2001-02-15 Fujisawa Pharmaceutical Co Verwendung von makrolid-verbindungen gegen augenerkrankungen
IL102414A (en) * 1991-07-25 1996-08-04 Univ Louisville Res Found Medicinal preparations for the treatment of ocular inflammation, containing rapamycin
AR004480A1 (es) * 1995-04-06 1998-12-16 Amico Derin C D Compuestos de ascomicina que poseen actividad antiinflamatoria, pro cedimiento para prepararlos, uso de dichos compuestos para preparar agentesfarmaceuticos y composiciones farmaceuticas que los incluyen
GB9601120D0 (en) * 1996-01-19 1996-03-20 Sandoz Ltd Organic compounds
JP2002509555A (ja) * 1998-04-06 2002-03-26 藤沢薬品工業株式会社 新規用途
ES2284248T3 (es) * 1998-04-27 2007-11-01 Astellas Pharma Inc. Formulacion farmaceutica en gel que comprende un compuesto triciclico (fk-506/tacrolimus).
US6376517B1 (en) * 1998-08-14 2002-04-23 Gpi Nil Holdings, Inc. Pipecolic acid derivatives for vision and memory disorders
WO2000066122A1 (en) * 1999-04-30 2000-11-09 Sucampo Ag Use of macrolide compounds for the treatment of dry eye

Also Published As

Publication number Publication date
HK1046099A1 (zh) 2002-12-27
JP2012116857A (ja) 2012-06-21
HK1043321B (zh) 2005-07-15
ES2232439T3 (es) 2005-06-01
BR0011225A (pt) 2002-03-19
AR023807A1 (es) 2002-09-04
EP1173177B2 (en) 2014-03-05
DE60015516D1 (de) 2004-12-09
JP5036934B2 (ja) 2012-09-26
PT1173177E (pt) 2005-03-31
HUP0200864A2 (hu) 2002-07-29
TR200103119T2 (tr) 2002-04-22
HK1043321A1 (en) 2002-09-13
EP1173177B1 (en) 2004-11-03
ATE281167T1 (de) 2004-11-15
CA2372448A1 (en) 2000-11-09
MXPA01010988A (es) 2004-04-21
TWI230066B (en) 2005-04-01
ZA200108905B (en) 2002-12-24
CZ20013769A3 (cs) 2002-03-13
KR20020015316A (ko) 2002-02-27
IL146162A0 (en) 2002-07-25
CN1190194C (zh) 2005-02-23
DE60015516T2 (de) 2005-12-01
WO2000066122A1 (en) 2000-11-09
NO20015288D0 (no) 2001-10-29
AU777915B2 (en) 2004-11-04
NZ515339A (en) 2004-02-27
JP2002543132A (ja) 2002-12-17
AU4142900A (en) 2000-11-17
EP1173177A1 (en) 2002-01-23
CN1353608A (zh) 2002-06-12
HUP0200864A3 (en) 2004-07-28

Similar Documents

Publication Publication Date Title
NO20015288L (no) Anvendelse av makrolide forbindelser for behandling av tört vye
NO20014379L (no) Anvendelse av Xenon for behandling av Neurointoksikasjoner
NO20021474L (no) Forbindelser for behandling av ischemi
NO20013369D0 (no) Arylpiperazinyl-cykloheksyl-indol-derivater for behandling av depresjon
NO20025792L (no) Kinazolinderivater for behandling av tumorer
NO20013380D0 (no) 2-aminobenzoksazinonderivater for behandling av fedme
FI20000863A (fi) Uusi hoitomenetelmä
NO20022087L (no) Fremgangsmåte for behandling av diabetes
NO20013381D0 (no) 2-oksybenzoksazinonderivater for behandling av fedme
NO20024775D0 (no) Hydroksyfenyl-piperidin-4-yliden-metyl-benzamidderivater til behandling av smerte
NO20023482D0 (no) Fremgangsmåte for behandling av stoffmisbruk
NO20022245L (no) Onkolyttiske kombinasjoner for behandling av cancer
NO20010953D0 (no) En fremgangsmÕte for behandling av stafylokokkal sykdom
NO20026219L (no) Forbindelser for behandling av svekket fundisk relaksasjon
NO20024777L (no) Kinolinyl-piperidin-4-yliden-metyl-benzamid derivater til behandling av smerte
NO20024776D0 (no) Hydroksyfenyl-piperazinyl-metyl-benzamidderivater til behandling av smerte
NO20020784D0 (no) Medikament for behandling av brudd
NO20012541D0 (no) Anvendelse av fosfonomaursyrederivater for behandling av infeksjoner
NO20000456D0 (no) Fremgangsmåte for fremstilling av 1,2-dikloretan
NO20012612L (no) Isonipecotamider for behandlingen av integrin-formidlede sykdommer
NO20012540D0 (no) Anvendelse av fosfonomaursyrederivater for behandling av infeksjoner
NO20013385L (no) S-nitrosotioler som midler for behandling av sirkulatoriske dysfunksjoner
NO20020328D0 (no) Fremgangsmåte for fremstilling av 4-cyano-2-aminometyltiazol
NO20005856L (no) Anvendelse av 1,1-diokso-perhydro-1,2,4-tiadiaziner
NO20020327D0 (no) Fremgangsmåte for fremstilling av 2-aminometyl-4-cyano-tiazol

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application